Scholars Central

Conference abstractPublished 1 Apr 2019

The study of chemotherapeutic activity of the ginsenoside Rh2 from ginseng root and doxorubicin combination treatment

Authors: Anna Klimovich, Alexander Popov, Olga Styshova

Russian Academy of Sciences, Russia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ginsenoside Rh2 (D-3β-O-glucopyranoside-20(S)-protopanaxadiol) increased the antitumor efficacy of doxorubicin (DOX) (anthracycline antitumor antibiotic) in the murine model of ascites Ehrlichâ??s adenocarcinoma. DOX-Rh2 co-treatment significantly prolonged the survival of tumor-inoculated animals compared to DOX treatment alone. Average survival of the untreated control group was 21 day, and for DOX and Rh2 alone treated groups were 70 and 65 day respectively. While the survival of the DOX-Rh2 cotreatment group was 95 day and 88% of the animals without symptoms of tumor were alive at the end of the 100 day observation period. In analysis with fluorescent indicator of the intracellular content of reactive oxygen species (ROS) - 2',7'-dichlorofluorescein diacetate, it has been shown that Rh2 is a stronger inducer of intracellular ROS level in the Ehrlich adenocarcinoma and splenocytes primary cells than DOX. Nevertheless, in DOX-Rh2 co-treated cell samples demonstrated no ROS increase in splenocytes. Rh2 was found to be a mild activator in the Neh2-luc reporter assay. Thus, Rh2 can protect of normal cells during oxidative stress by activation of transcription factor Nrf2-driven cytoprotective programs. Hence, Rh2 can minimize DOX side effects associated with oxidative damage of normal cells, but at the same time Rh2 maintains optimal ROS level sufficient for DOX-Rh2 cytotoxicity against cancer cells. It is suggested that trigger of Rh2 antitumor effect is due to its direct interaction with the plasma membrane lipids. Thereby, Rh2 increases membrane permeability for DOX and ROS in cancer cell that probably enhances DOX cytotoxicity and overcome drug resistance caused by efflux of anticancer drugs from the tumor cells.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medicinal Chemistry.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Anna Klimovich”
  • BylineArticles whose byline prints “Alexander Popov”
  • BylineArticles whose byline prints “Olga Styshova”